Advances in Breast Cancer
|
|
- Rose Shaw
- 5 years ago
- Views:
Transcription
1 Advances in Breast Cancer Developed in collaboration Learning Objectives Upon completion, participants should be able to: Apply genomic medicine to treatment decisions for patients with HR+/HER2- early stage breast cancer Assess the range of radiotherapy doses and fractionation schemes that may be appropriate for patients with early stage breast cancer who undergo breast-conserving surgery Evaluate select clinical studies on the latest surgical techniques in breast cancer 1
2 Genomic Signatures: Changing the Face of HR+ Breast Cancer Jeremy Force, DO 21-Gene RS Assay 16 Breast Cancer Related Genes Estrogen Proliferation HER2 Invasion Others ER PR Bcl2 SCUBE2 Ki-67 STK15 Survivin Cyclin B1 MYBL2 GRB7 HER2 Stromelysin 3 Cathepsin L2 CD68 GSTM1 BAG1 5 Reference Genes Beta-actin GAPDH RPLPO GUS TFRC Paik S, et al. N Engl J Med. 2004;351:
3 The RS Result Reveals Individual Tumor Biology for ER+, LN-Negative Breast Cancer Treated With ET Distant Recurrence at 10 Years Continuous Biology 40% 35% 30% 25% 20% 15% 10% 5% 0% RS Value Low RS Disease Indolent Hormonal therapy sensitive Minimal, if any, chemotherapy benefit High RS Disease Aggressive Less sensitive to hormonal therapy Large chemotherapy benefit Paik S, et al. N Engl J Med. 2004;351: ; Paik S, et al. J Clin Oncol. 2006;24: The RS Result Identifies Patients With ER+ Tumors Who Would Derive the Greatest Benefit From Chemotherapy 1.0 Proportion Without Distant Recurrence All patients RS < 18 RS RS 31 *N = 651. Paik S, et al. J Clin Oncol. 2006;24: Tamoxifen + chemotherapy Tamoxifen Tamoxifen + chemotherapy Tamoxifen Tamoxifen + chemotherapy Tamoxifen Tamoxifen + chemotherapy Tamoxifen n* N Events P =.02 P =.61 P =.39 P < Years PATIENTS WITH HIGH RS 28% absolute benefit from tamoxifen + chemotherapy 3
4 Background: Rationale for Adjusting RS Ranges in TAILORx: Large Chemotherapy Benefit in NSABP B-20 With RS > 25 Similar to RS 31 Patients 10-Year DRFS (%) Recurrence by Addition of Chemotherapy RS No. % Tam Tam+Chemo HR 95% CI P Value to to to <.0001 Sparano JA, et al. J Clin Oncol. 2008;26: TAILORx Methods: Treatment Assignment and Randomization Accrued Between April 2006 October 2010 Preregister: 21-Gene RS Assay (N = 11,232) Register (N = 10,273) ARM A: Low RS 0-10 (n = 1,619 evaluable) ASSIGN ET Mid-Range RS (n = 6,711 evaluable) RANDOMIZE Stratification Factors: Menopausal Status, Planned Chemotherapy, Planned Radiation, and RS 11-15, 16-20, ARM D: High RS (n = 1,389 evaluable) ASSIGN ET + Chemo ARM B: Experimental Arm (n = 3,399) ET Alone ARM C: Standard Arm (n = 3,312) ET + Chemo Sparano JA, et al. N Engl J Med. 2018;379:
5 TAILORx: RS < 11 A IDFS Months Probability of DFS C Freedom From Recurrence at Any Site Probability of Freedom From Event Months B Freedom From Recurrence of Breast Cancer at Distant Site Probability of Freedom From Event D OS Months From N Engl J Med, Sparano JA, et al. Prospective validation of a 21-gene expression assay in breast cancer, vol 373, p Copyright Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. Probability of Survival Months ER/PR+ HER2- LN negative Tumor cm or, if grade 3, cm n = 1, % 5-yr DFS 98.0% 5-yr OS TAILORx: RS DFS Probability Arm C Chemo + ET Arm B ET Alone P =.26 HR Arm B vs Arm C (95% CI) 1.08 (0.94, 1.24) 836 IDFS events after median of 7.5 years 338 of 836 (40.3%) with recurrence as first event 199 of 836 (23.8%) were distant recurrence Months Number at Risk Arm C Chemo + ET 3,312 3,204 3,104 2,993 2,849 2,645 2,335 1,781 1, Arm B ET Alone 3,399 3,293 3,194 3,081 2,953 2,741 2,431 1,859 1, From N Engl J Med, Sparano JA, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, vol 379, p Copyright Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society. 5
6 TAILORx-Defined Cutoff for Definitively Determining Chemotherapy Benefit With the 21-Gene RS Assay (LN-Negative, HR+, HER2-) Subgroup Age 50 Years RS 0-10 RS RS RS RS No CT benefit No CT benefit ~1.5% CT benefit ~7% CT benefit Large CT benefit ~50% of patients 50 years have RS 0-15, 35% RS 16-25, and 15% RS Sparano JA, et al. J Clin Oncol. 2018;36:abstract LBA1. Conclusion The 21-gene RS assay is a well-validated tool for use in women with HR+/HER2-, LN-negative breast cancer Postmenopausal women with HR+/HER2-, LN-negative breast cancer and RS 25 can safely forgo chemotherapy Premenopausal women with HR+/HER2-, LN-negative breast cancer and RS warrant a conversation about potential chemotherapy benefit Please also see position statements and practice guidelines for warnings, efficacy, risks, and safety associated with the treatment strategies discussed. 6
7 Radiotherapy Fractionation for Early Stage Breast Cancer Rachel Blitzblau, MD, PhD Goals Focus: external beam options Brachytherapy options also available and appropriate for select patients 7
8 Radiotherapy Fractionation Radiotherapy is most often a series of daily treatments over a number of weeks Each of these treatments is a fraction of radiotherapy Number of fractions and final dose varies by cancer type and patient factors Historically, after breast-conserving surgery, breast cancer patients received 5-8 weeks of daily treatments to the entire breast Growing evidence shows that shorter fractionation schedules and/or treatment of just a part of the breast is equally effective for select breast cancer patients Smith BD, et al. Pract Radiat Oncol. 2018;8:145-52; Salerno KE. J Natl Compr Canc Netw. 2017;15: Hypofractionated Whole Breast Radiotherapy Local Recurrence, % Survival, % Cosmesis, % Follow-Up, Trial N Long Short Long Short Long Short Years Whelan et al 1,2 1, years START A 3,4 2, ; ; 79.7 late 10 years START B 3,4 2, late 10 years 1. Whelan T, et al. J Natl Cancer Inst. 2002;94: Whelan TJ, et al. N Engl J Med. 2010;362: START Trialists Group. Lancet Oncol. 2008;9: Haviland JS, et al. Lancet Oncol. 2013;14:
9 2018 ASTRO Consensus Statement HF-WBI Wider application of HF-WBI, shared decision making Age: any (prior: 50 years) Stage: any when intent is to treat entire breast without regional nodal fields (prior: T1/2 N0) Chemotherapy: any (prior: none) Dose homogeneity: minimize 105% for all fractionation (prior: +/- 7%) Also greater evidence now for use in DCIS patients Smith BD, et al. Pract Radiat Oncol. 2018;8: Partial Breast Irradiation 1 Preoperative Treat intact tumor before surgery Clinical trials published Ongoing clinical trials Intraoperative Single dose in OR after lumpectomy performed TARGIT and ELIOT trials 2-4 Postoperative 1 week Classic APBI 10 treatments, twice daily, 5 days External beam or brachytherapy NSABP B-39 and many other trials 5 Postoperative 3 weeks Mini tangents 15 fractions (START) 6 IMPORT LOW trial 7 1. Correa C, et al. Pract Radiat Oncol. 2017;7: Veronesi U, et al. Lancet Oncol. 2013;14: Vaidya JS, et al. Lancet. 2010;376: Vaidya JS, et al. Lancet. 2013;383: ClinicalTrials.gov. NCT Haviland JS, et al. Lancet Oncol. 2013;14: Coles CE, et al. Lancet. 2017;390:
10 ASTRO Consensus Statement APBI Patients suitable for APBI if all criteria are present Factor Criterion Patient factors Age 60 y 50 y BRCA1/2 mutation Not present Pathologic factors Tumor size 2 cm T stage T1 Tis or T1 Margins Negative by at least 2 mm Grade Any LVSI No ER status Positive Multicentricity Unicentric only Multifocality Clinically unifocal with total size 2.0 cm Histology Invasive ductal or other favorable subtypes Pure DCIS Not allowed Low-risk DCIS EIC Not allowed RTOG 9804 Associated LCIS Allowed Nodal factors N stage pn0 (i-, i+) Nodal surgery SLNB or ALND Treatment factors Neoadjuvant therapy Not allowed Cautionary group: Any of these criteria should invoke caution and concern when considering APBI Factor Criterion Patient factors Age y y > 50 if don t meet suitable Pathologic factors Tumor size cm T stage T0 or T2 Margins Close (< 2 mm) LVSI Limited/focal ER status Negative Multifocality Clinically unifocal with total size cm Histology Invasive lobular Pure DCIS 3 cm And not in suitable EIC 3 cm Smith BD, et al. J Am Coll Surg. 2009;209:269-77; Correa C, et al. Pract Radiat Oncol. 2017;7:73-9. Patients unsuitable for APBI outside of a clinical trial if any of these criteria are present Factor Criterion Patient factors Age < 50 y < 40 y if don t meet cautionary BRCA1/2 mutation Present Pathologic factors Tumor size > 3 cm T stage T3-4 Margins Positive LVSI Extensive Multicentricity Present Multifocality If microscopically multifocal > 3 cm in total size or if clinically multifocal Pure DCIS If > 3 cm in size EIC If > 3 cm in size Nodal factors N stage pn1, pn2, pn3 Nodal surgery None performed Treatment factors Neoadjuvant therapy If used UK IMPORT LOW Trial Multicenter, randomized, phase 3 noninferiority trial, N = 2,018; women age > 50 years, pt1-2 (< 3 cm), pn0-1, margins 2 mm Procedures (all 15 fractions): 1: 40 Gy whole breast (control) 2: 36 Gy whole breast and 40 Gy partial breast (reduced-dose group) 3: 40 Gy partial breast (partial-breast group) Field-in-field, tangential beams (reduced tangents for partial breast) Primary: ipsilateral in breast relapse Relapse at 5 years: 1: 1.1%; 2: 0.2%; 3: 0.5% Conclusion: partial breast and reduced-dose whole breast radiotherapy are noninferior Coles CE, et al. Lancet. 2017;390:
11 Conclusion Women with early stage, LN-negative breast cancer have many potentially appropriate radiotherapy treatment regimens Whereas historically the whole breast was treated for 5-7 weeks, there are now significant and growing data to support shorter treatment courses and partial breast regimens The vast majority of women with early stage breast cancer should now receive treatment courses of 1-4 weeks duration Please also see position statements and practice guidelines for warnings, efficacy, risks, and safety associated with the treatment strategies discussed. Hot Topics in Breast Cancer Surgery Jennifer K. Plichta, MD, MS 11
12 Lumpectomy Today Oncologically safe in the modern era Meta-analysis of nearly 7,000 patients with stage I-III breast cancer in 9 clinical trials Overall 5-year local recurrence rates after breast-conserving surgery: 4.2% (historical rates: 5%-10%) 7.0% 6.0% 5.0% 4.0% 3.0% 2.0% 1.0% 0.0% 5 Year Local Recurrence Rates 6.4% 4.9% 4.2% 3.2% 3.6% Neuman H, et al American Society of Breast Surgeons Annual Meeting. Abstract NSM Oncologically safe in BRCA mutation carriers risk-reducing NSMs in 346 patients at 9 institutions No breast cancers observed; median follow-up of 34 months (expected 22) Does not delay adjuvant therapy 2 NSM on 8,173 patients in NCDB: 8.7% N+, 10.6% triple negative,15.3% HER2+ Readmission rate; positive margin rate and time to chemotherapy; PMRT or hormonal therapy similar for NSM and SSM patients Photo from DellaCroce FJ, et al. Plast Reconstr Surg. 2015;136:1e. 1. Jakub JW, et al. JAMA Surg. 2018;153: Albright EL, et al. Ann Surg Oncol. 2018;25:
13 CPM Surgeons influence CPM choice Population-based survey 5,080 women, stages 0-II breast cancer treated (70% response rate) 377 surgeons (77% response rate) Attending surgeon: explains 20% of variation in CPM rates Attending attitudes: explains 25% of surgeon influence CPM rate 34% vs 4% for surgeons who least favored vs most favored breast conservation Katz SJ, et al. JAMA Surg. 2018;153: In this scenario would you recommend Def. No Prob. No Prob. Def. Yes Def. No Prob. No Prob. Def. Yes Fraction For CPM Against CPM For mastectomy For BCS Peace of Mind Avoid Surveillance Avoid Conflict Improve QOL (N = 370) If requested by patients Scenario (N = 370): A 55 year old with no family history of breast with no family history cancer has a normal screening mammogram. A bilateral screening ultrasound shows a 1.2-cm solid mass. Core biopsy demonstrates classic infiltrating ductal carcinoma. ER 95%, PR 90%, and HER2-negative. I might perform CPM for/to Cosmetic Reasons Avoid Losing Patient Reduce Recurrence Improve Survival Fraction Very likely Quite likely Somewhat A bit likely Not likely TAD TAD = SLNB + removal of clipped/biopsied node Removing the clipped/biopsied node improves axillary evaluation after NACT patients, 191 ALND, residual disease in 120 (63%) FNR for clipped node alone: 4.2% (95% CI, 1.4 to 9.5) FNR for SLNB and ALND: 10.1% (95% CI, 4.2 to 19.8) Clipped node was not retrieved as SLN in 23% FNR TAD followed by ALND: 2.0% (1 of 50; 95% CI, 0.05 to 10.7) ACOSOG Z1071 (analysis of clipped nodes) with clipped node, clinical T0-T4,N1-N2,M0 breast cancer, SLNB and ALND FNR for SLNB + clipped node: 6.8% (CI 1.9% to 16.5%; P =.20) 1. Caudle AS, et al. J Clin Oncol. 2016;34: Boughey JC, et al. Ann Surg. 2016;263: Figure reprinted with permission American Society of Clinical Oncology. All rights reserved. 13
14 Timing of Surgery Higher local recurrence rates after breast-conserving therapy for tumor downsized by NACT 4,756 women in 10 randomized trials in early breast cancer, , median follow-up of 9 years 15-year local recurrence rate: NACT 21.4% vs ACT 15.9% (P =.0001) No significant differences in distant recurrence, breast cancer mortality, or death from any cause Local Recurrence, % NACT ACT 4,756 women, 635 events 15-year loss: 5.5% (95% CI, ) RR, 1.37 (95% CI, ) Log-rank P = % Years Local Recurrence Crude Rates (Events per Woman-Years) and Log-Rank Analyses Years 0-4 Years 5-9 Years Years 15 Neoadjuvant 2.58 (245/9,493) 1.43 (79/5528) 0.93 (26/2,784) 2.16 (16/740) Adjuvant 1.95 (185/9,477) 0.96 (54/5,618) 0.69 (19/2,769) 1.42 (11/772) Rate ratio 1.35 ( ) 1.53 ( ) 1.29 ( ) 1.11 ( ) (95% CI) from 30.4/ / / /5.4 (O-E)/V Early Breast Cancer Trialists Collaborative Group (EBCTCG). Lancet Oncol. 2018;19: % 9.0% % 21.4% 15.9% Avoiding Surgery? No surgery for pcr patients 1 Feasibility study of 40 patients with HER2+ or triple-negative T1-3/N0-1 Breast pcr rate: 48% Median initial tumor size was 3.3 cm; final tumor size was 1.1 cm FNA + vacuum-assisted core biopsy: accuracy 98%, FNR 5%, NPV 95% Active surveillance for DCIS 2 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial Women 40 years; any grade I DCIS or any grade II DCIS without comedonecrosis; ER+ and/or PR+ Guideline-concordant care (surgery +/- radiation, ET) vs active surveillance (ET) Primary outcome: proportion of new ipsilateral breast cancers at 2 years follow-up 1. Kuerer HM, et al. Ann Surg. 2018;267: ClinicalTrials.gov. NCT
15 Conclusion Contemporary local recurrence rates after breast-conserving therapy are lower today NSMs are oncologically safe in BRCA-mutation carriers and do not delay adjuvant therapies Targeted axillary dissections may become the standard of care for patients with excellent responses to NACT Some patients may have a higher risk of local recurrence after NACT and breast-conserving surgery Studies evaluating the possibility of omitting surgery for select breast cancer patients are ongoing; stay tuned! Please also see position statements and practice guidelines for warnings, efficacy, risks, and safety associated with the treatment strategies discussed. Contact Information Call (toll-free) info@med-iq.com Please visit us online at for additional activities provided by Med-IQ. 15
16 2018 Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors. 16
17 Breast Cancer: Abbreviations and Acronyms ACT = adjuvant chemotherapy ALND = axillary lymphadenectomy APBI = accelerated partial breast irradiation BAG1 = Bcl-2 athanogene-1 Bcl2 = B-cell lymphoma 2 BRCA = breast cancer susceptibility gene CPM = contralateral prophylactic mastectomy CT = chemotherapy DCIS = ductal carcinoma in situ DFS = disease-free survival DRFS = distant recurrence free survival EIC = extensive intraductal component ER = estrogen receptor ET = endocrine therapy FNA = fine-needle aspiration FNR = false-negative rate GAPDH = glyceraldehyde 3-phosphate dehydrogenase GRB7 = growth factor receptor bound protein 7 GSTM1 = glutathione-s-transferase M1 HER2 = human epidermal growth factor receptor 2 HF-WBI = hypofractionated whole-breast irradiation HR = hormone receptor IDFS = invasive disease-free survival LCIS = lobular carcinoma in situ LN = lymph node LVSI = lymph-vascular space invasion MYBL2 = MYB proto-oncogene like 2 NACT = neoadjuvant chemotherapy NCDB = National Cancer Database NPV = negative predictive value NSABP = National Surgical Adjuvant Breast and Bowel Project NSM = nipple-sparing mastectomy OS = overall survival pcr = pathologic complete response PMRT = postmastectomy radiotherapy PR = progesterone receptor QOL = quality of life RPLPO = ribosomal protein lateral stalk subunit P0 RS = recurrence score SCUBE2 = signal peptide-cub-epidermal growth factor-like domain-containing protein 2 SLNB = sentinel lymph node biopsy SSM = skin-sparing mastectomy TAD = targeted axillary dissection TFRC = transferrin receptor
Genomic Profiling of Tumors and Loco-Regional Recurrence
1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationRationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York
Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationIntraoperative. Radiotherapy
Intraoperative Radiotherapy ROBERTO ORECCHIA UNIVERSITY of MILAN & EUROPEAN INSTITUTE of ONCOLOGY & CNAO FOUNDATION Breast Cancer Brescia, 30th September 2011 IORT, very selective technique to intensify
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationRecent Update in Surgery for the Management of Breast Cancer
Recent Update in Surgery for the Management of Breast Cancer Wonshik Han, MD, PhD Professor, Department of Surgery, Seoul National University College of Medicine Chief of Breast Care Center, Seoul National
More informationShe counts on your breast cancer expertise at the most vulnerable time of her life.
HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationIs Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?
Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Mylin A. Torres, MD Director, Glenn Family Breast Center Louis and Rand Glenn Family Chair in Breast
More informationCurrent Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology
Current Status of Accelerated Partial Breast Irradiation Julia White MD Professor, Radiation Oncology I have no disclosures relative to the presented material Agenda ABPI Timeline APBI by Method Clinical
More informationBreast Conservation Therapy
May 18, 2018 Breast Conservation Therapy One Treatment No Longer Fits All Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. Define stages of breast cancer that are candidates
More informationResults of the ACOSOG Z0011 Trial
DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationSurgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery
Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationdoi: /j.ijrobp
doi:10.1016/j.ijrobp.2009.12.047 Int. J. Radiation Oncology Biol. Phys., Vol. 79, No. 4, pp. 977 984, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ see front matter
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationClinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
More informationSeigo Nakamura,M.D.,Ph.D.
Seigo Nakamura,M.D.,Ph.D. Professor of Surgery Director of Breast Center Showa University Hospital Chairman of the board of directors Japan Breast Cancer Society Inhibition of Estrogen-Dependent Growth
More informationDebate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest
Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,
More informationRadiation Therapy for the Oncologist in Breast Cancer
REVIEW ARTICLE Chonnam National University Medical School Sung-Ja Ahn, M.D. Adjuvant Tamoxifen with or without in Patients 70 Years of Age with Stage I ER-Positive Breast Cancer: Efficacy Outcomes (10
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationSurgical Considerations in Breast Cancer treated with Neoadjuvant Therapy
Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy Rebecca Warburton MD Department of Surgery, University of British Columbia Mount Saint Joseph Hospital, Providence Health Care
More informationThe Oncotype DX Assay A Genomic Approach to Breast Cancer
The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast
More informationDisclosure. Objectives 03/19/2019. Current Issues in Management of DCIS Radiation Oncology Considerations
Current Issues in Management of DCIS Radiation Oncology Considerations Fariba Asrari, M.D. Director. Johns Hopkins Breast Center at Green Spring Station Department of Radiation Oncology & Molecular Sciences
More informationTargeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center
Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic
More informationNSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions
1 1 NSABP Pivotal Breast Cancer Clinical Trials: Historical Perspective, Recent Results and Future Directions Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health
More informationBREAST CANCER. Dawn Hershman, MD MS. Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center.
BREAST CANCER Dawn Hershman, MD MS Florence Irving Assistant Professor of Medicine and Epidemiology Co-Director, Breast Program HICCC Columbia University Medical Center Background Breast cancer is the
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
- Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationWhole Breast Irradiation: Class vs. Hypofractionation
Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer
More informationTAILORx: Established and Potential Implications for Clinical Practice
TAILORx: Established and Potential Implications for Clinical Practice Joseph A. Sparano, MD Study Chair, TAILORx Vice-Chair, ECOG-ACRIN Cancer Research Group Hello Healthcare Summit Berlin, Germany March
More informationFeasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study
[ABS-0078] GBCC 2018 Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study Eun Young Kim 1, Kwan Ho Lee 1, Yong
More informationIs Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013
Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013 Changing Phases claudin low Lum A Lum B Basal Her2 NIH Consensus Development Panel,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationRecent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective
Recent Updates in Surgical Management of Breast Cancer Asian Patient's Perspective Tokyo-West Tokushukai Hospital Department of Breast Oncology Tokyo-West Tokushukai Hospital, Tokyo, Japan Kaz Sato, MD,
More informationIORT What We ve Learned So Far
IORT What We ve Learned So Far The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation
More informationMolecular Characterization of Breast Cancer: The Clinical Significance
Molecular Characterization of : The Clinical Significance Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville
More informationAdvances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationObjectives Intraoperative Radiation Therapy for Early Stage Breast Cancer
Objectives Intraoperative Radiation Therapy for Early Stage Breast Cancer Cristina Lopez-Peñalver, MD, FACS October 11, 2014 Disclosures I have no relevant commercial relationships to disclose. Discuss
More informationCancer. Savita Dandapani
New Modalities for Breast Cancer Savita Dandapani Disclosures Accuray Talk at ASTRO 10/2015. Xoft provided slides for the partial breast radiation equipment. Early Stage: Deep Inspiratory Breath Hold (DIBH)
More informationPage 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.
AHN-JHU Breast Cancer Symposium Novel Local Regional Clinical Trials March 22, 2019 Thomas B. Julian, MD, FACS Associate Medical Director, Cancer Program Development, ANH Cancer Institute Background In
More informationPartial Breast Irradiation for Breast Conserving Therapy
To Radiate or Not? Is APBI the Right Compromise Solution? Partial Breast Irradiation for Breast Conserving Therapy Julia White MD Professor, Radiation Oncology Agenda Role of radiotherapy in breast conservation
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationHypofractionated Radiotherapy for breast cancer: Updated evidence
2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial
More informationThe Role of Sentinel Lymph Node Biopsy and Axillary Dissection
The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical
More informationIndications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer
Indications and Technical Considerations for Adjuvant Radiation after Neoadjuvant Chemotherapy in Breast Cancer Wendy A. Woodward, M.D. Ph.D. A sociate Profesor Section Chief, Breast Radiation Oncology
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationInvasive Breast Cancer
Invasive Breast Cancer Eileen Rakovitch MD MSc FRCPC Sunnybrook Health Sciences Centre Medical Director, Louise Temerty Breast Cancer Centre LC Campbell Chair in Breast Cancer Research Associate Professor,
More informationThe TAILORx Trial: A review of the data and implications for practice
The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University
More informationBreast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015
Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More information2017 Topics. Biology of Breast Cancer. Omission of RT in older women with low-risk features
2017 Topics Biology of Breast Cancer Early-stage HER2+ breast cancer-can we avoid RT? Prediction tools for locoregional recurrence Omission of RT in older women with low-risk features Local-Regional Recurrence
More informationThe Latest Research: Hormonal Therapies
The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures
More informationBreast Cancer: Current Approaches to Diagnosis and Treatment
Breast Cancer: Current Approaches to Diagnosis and Treatment Barbara L. Smith, MD, Ph.D. Massachusetts General Hospital Division of Surgical Oncology No Disclosures Incidence of Breast Cancer USA 2018
More informationPosition Statement on Management of the Axilla in Patients with Invasive Breast Cancer
- Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the
More informationCURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!?
CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!? I have no Disclosures Wolfgang Gatzemeier Breast Unit Milan, Italy 17th ESO-ESMO- EONS Masterclass in Clinical Oncology 24-29 MARCH 2018 Optimal
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
:$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER
ACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER KHANH NGUYEN, MD, MA DEPARTMENT OF RADIATION ONCOLOGY BAYHEALTH CANCER CENTER BREAST CANCER STATISTICS Most common
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More information16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes
ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,
More informationWhat is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine
What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells
More informationConservative Surgery and Radiation Stage I and II Breast Cancer
Conservative Surgery and Radiation Stage I and II Breast Cancer Variant 1: Premenopausal 41-year-old woman, 1.1-cm GII IDC, upper outer quadrant (UOQ), ER/PR ( ), HER2 ( ), primary excised with lumpectomy,
More informationEvolution of Breast Surgery
Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,
More information30 years of progress in cancer research
Breast Cancer Molecular Knowledge Integrated in Clinical Practice Personalized Medicine Laura J. Esserman UCSF Comprehensive Cancer Center Retreat Breast Cancer Management Advances 80-90s 1) Screening
More informationOne Breast Cancer Annual Report
One 2015 Breast Cancer Annual Report One OVERVIEW The Breast Program at Carolinas HealthCare System s Levine Cancer Institute, offers comprehensive care. Patients with benign and malignant disease of the
More informationSurgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy
Surgical treatment of BRCA mutated patients Viviana Galimberti MD European Institute of Oncology Milan, Italy No pharmaceutical company funding was used I declare I have no conflicts of interest as regards
More informationUltrasound or FNA for Predicting Node Positive in Breast Cancer
Ultrasound or FNA for Predicting Node Positive in Breast Cancer Chiun Sheng Huang, MD, PhD, MPH Professor and Chairman Department of Surgery Director of Breast Care Center National Taiwan University Hospital
More informationARROCase - April 2017
ARROCase - April 2017 Radiation Indications in the setting of Neoadjuvant chemotherapy for Breast Cancer Lauren Colbert, MD, MSCR Faculty Mentor: Benjamin Smith, MD UT MD Anderson Cancer Center 37 year
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationEARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT
May 13, 2016 EARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. List treatment options for early stage breast cancer. 2.
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006
Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane
More informationClinical Investigation: Breast Cancer
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation: Breast Cancer How Do the ASTRO Consensus Statement Guidelines for the Application of Accelerated Partial
More informationCase Conference: Post-Mastectomy Radiotherapy
Case Conference: Post-Mastectomy Radiotherapy Outline - Case Intro Guidelines Studies - Case Conclusion Summary Outline Case Intro to PMRT Guidelines Studies Case conclusion Summary Outline - Case Intro
More informationNew Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationSSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Dr. Yvonne Tsang St. Paul s Hospital Introductions Breast-conserving
More informationSentinel Lymph Node Biopsy for Breast Cancer
Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor
More informationASTRO Refresher Course 2016 Breast Cancer
ASTRO Refresher Course 2016 Breast Cancer Jennifer R. Bellon, M.D. Dana-Farber Cancer Institute Associate Professor of Radiation Oncology Harvard Medical School I have no relevant conflicts of interest
More informationTHE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE. Dr Husam Marashi 03/02/2017
THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE Dr Husam Marashi 03/02/2017 THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER TODAY S TALK: CENTRE EXPERIENCE
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationCan We Omit Surgery with Suggestion of pcr by Biopsy in Breast? Fudan University Shanghai Cancer Center Ke-Da Yu, M.D.
Can We Omit Surgery with Suggestion of pcr by Biopsy in Breast? Fudan University Shanghai Cancer Center Ke-Da Yu, M.D. I have no relevant financial relationship with commercial interests to disclose. More
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationRadiotherapy Implications of ACOSOG Z-11 for Clinical Practice. Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin
1 Radiotherapy Implications of ACOSOG Z-11 for Clinical Practice Julia White, MD Professor of Radiation Oncology Medical College of Wisconsin Disclosures: none Agenda 1. ACOSOG Z-11: Another perspective
More informationMastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data
Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data Nathalie Johnson, MD FACS Medical Director, Legacy Cancer Institute and Breast Health Centers Objectives Understand
More information2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights
2017 San Antonio Breast Cancer Symposium: Local Therapy Highlights Mylin A. Torres, M.D. Director, Glenn Family Breast Center Associate Professor Department of Radiation Oncology Winship Cancer Institute
More informationBreast cancer: Clinical evidence. of new treatments. Aero academy Conference Innovation and Safety. Patients Come First
Breast cancer: Clinical evidence of new treatments Aero academy Conference Innovation and Safety Patients Come First January 26 & 27, 2018 Lisbon, Portugal Disclosure & Disclaimer An honorarium is provided
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More information